Sphaera Pharma Pvt. Ltd

Sphaera Pharma Pvt. Ltd is an Indian pharmaceutical company focused on drug discovery and development, delivering comprehensive preclinical research services to enhance patient care across various therapeutic domains. Founded in 2007 in Gurgaon, India, Sphaera Pharma specializes in drug discovery and development. The company has not undergone any known pivots or changes in strategy.

Sundeep Dugar, the founder, has a background in the pharmaceutical sector. Sphaera Pharma has raised a total of INR 597. 520 mn, most recently in a GROWTH round led by Baring Private Equity Partners. Sphaera Pharma specializes in drug discovery and development, providing integrated preclinical research services that include new chemical entity (NCE) design and synthesis, hit-to-lead and lead optimization, in-vitro pharmacology, and in-vivo pharmacology studies.

They focus on therapeutic areas such as oncology, metabolic disorders, CNS disorders, mitochondrial dysfunction, and rare genetic diseases. The company's collaboration with global partners allows them to deliver tailored solutions for pharmaceutical companies, biotechnology firms, and research institutions primarily in North America, Europe, and Asia. In 2023, Sphaera Pharma reported a revenue of INR 886059. 7 and an EBITDA of -INR 1337082.

The company's revenue primarily comes from partnerships and collaborations in the life sciences sector, operating on a B2B model that includes fee-for-service agreements and milestone-based payments tied to project progression. Sphaera Pharma plans to leverage its recent funding to expand its product offerings and enhance its market presence. The company is actively working on new drug development projects aimed at addressing unmet medical needs in specific therapeutic areas. They are targeting expansion into markets across Europe and North America by the end of 2024, utilizing the INR 597.

520 mn from their latest funding round to support these initiatives. The exit of Baring Private Equity Partners from their stake marks a new chapter in their strategic growth.